Skip to content
SPY$715.87down −1.96%
Nasdaq$645.04down −2.19%
Nvidia$145.98down −3.30%
SpaceX$138.43down −3.53%
BTC$61,560.00down −1.94%
Gold$3,552.61down −5.17%
Silver$42.27down −8.27%
Brent oil$92.50up +0.37%
DXY103.72down −0.07%
EUR/USD1.0964down −0.09%
USD/JPY159.30down −0.29%
2Y yield4.76%down −4 bp
5Y yield4.86%down −3 bp
10Y yield5.04%down −3 bp

Search FinPrism

Companies · · 3 min read

Editor: Bohdan S.

Johnson & Johnson agrees to buy Ollin Biosciences for up to $3.3 billion

J&J will pay $2.2 billion upfront for the eye disease biotech, plus milestones, to gain a late-stage retinal drug that it hopes can rival Roche's Vabysmo.

Johnson & Johnson agrees to buy Ollin Biosciences for up to $3.3 billion

The short answer

Johnson & Johnson said on Monday it will acquire Texas-based Ollin Biosciences for $2.2 billion upfront plus up to about $1.125 billion in milestones. The deal brings OLN324, a Phase 3 drug for wet AMD and diabetic macular edema. The Financial Times (FT) said it is part of a wave of biotech takeovers.

What happened

Johnson & Johnson (JNJ) announced on Monday a definitive agreement to buy Ollin Biosciences, a privately held company founded in 2023 that develops treatments for serious eye diseases. According to the J&J release, it will pay $2.2 billion in cash upfront, and Ollin's owners could receive up to roughly $1.125 billion more if regulatory and sales goals are met. Separately, Blackstone Life Sciences will give J&J $750 million over several years to cover Phase 3 testing of Ollin's lead drug. Both steps depend on the deal closing, which J&J expects before the end of 2026. The Financial Times (FT) reported the purchase as the latest in a flood of biotech deals.

What it means

The prize is OLN324, an experimental antibody that blocks two signals involved in retinal disease, known as VEGF and Ang2. It is aimed at wet age-related macular degeneration (AMD) and diabetic macular edema, which J&J says together affect more than 40 million people worldwide and are major causes of lost sight. The drug is a bispecific antibody, meaning one molecule hits two targets, and it comes in a small format that J&J says could control fluid in the retina better and allow longer gaps between treatments.

The early evidence is the reason for the price. In a head-to-head study called JADE, OLN324 produced faster and larger improvements in the structure of the eye, plus bigger vision gains, than Vabysmo in both conditions, according to Ollin as reported by CNBC and BioSpace. Vabysmo is a blockbuster Roche drug sold through its Genentech unit, and it already targets the same two pathways. Reports describe the JADE trial as early or mid stage, so the larger Phase 3 program still has to confirm those results.

For J&J, this is a move into a field where it is a small player. The company is best known in eye care for Acuvue contact lenses and Tecnis lenses used in cataract surgery, but it sells no drugs for retinal disease, BioSpace noted. Its earlier attempts have stumbled: a gene therapy for an inherited retinal condition, partnered with MeiraGTx, missed in Phase 3 and was handed back this spring, and a gene therapy from Hemera Biosciences for geographic atrophy was dropped over the summer.

The Blackstone piece of the deal is worth a closer look. Instead of paying for the costly final trials itself, J&J gets outside money and in return gives Blackstone the right to future milestone payments and single-digit royalties on sales. BioSpace pointed out that Blackstone agreed a similar arrangement of up to $1.5 billion with Pfizer for an obesity drug last week, and one with Merck in 2025.

The bull case

J&J gets a Phase 3 drug that has already outperformed the market leader in a direct comparison. Blackstone's $750 million covers the trial bill, limiting J&J's cash outlay, and much of the remaining price is paid only if the drug succeeds. A win would give J&J a foothold in a large retinal market where it has no products today.

The bear case

Strong results in a smaller trial do not always hold up in Phase 3, and J&J's own retinal programs have already failed twice this year. Vabysmo is entrenched with eye doctors, so even a better drug may take time to win share. Sharing royalties with Blackstone also trims J&J's future profit if OLN324 becomes a large seller, and the deal still needs regulatory approval.

Why it matters

For investors

The deal adds to signs that big drugmakers are willing to pay billions for late-stage assets, which could support sentiment toward private and listed biotech developers. For J&J shareholders, the value of the purchase will hinge on Phase 3 results.

The wider context

Large drugmakers are buying younger companies to refill their pipelines, which can reward investors in biotech funds. Patients with retinal disease could eventually get more treatment choices, though OLN324 still has to pass Phase 3 and win approval.

Market impact

Asset (ticker)Possible moveTimeframeWhy
Johnson & Johnson (JNJ) ↑ Up Long term Adds a late-stage retinal drug with outside trial funding, but success depends on Phase 3 results.

The FinPrism newsroom's view of how these figures could move, as of . It is general news commentary, not a recommendation to buy, sell or hold anything.

Frequently asked questions

How much is Johnson & Johnson paying for Ollin Biosciences?

J&J will pay $2.2 billion upfront for Ollin, and the biotech's owners could receive up to about $1.125 billion more in milestone payments tied to regulatory and sales goals. That puts the total potential value at roughly $3.3 billion. The deal is expected to close before the end of 2026.

What is OLN324 and what does it treat?

OLN324 is an experimental bispecific antibody from Ollin that blocks two drivers of retinal disease, VEGF and Ang2. It is being developed for wet age-related macular degeneration and diabetic macular edema, two leading causes of vision loss. It is now entering Phase 3, the final stage of testing before approval.

Why is Blackstone involved in the J&J Ollin deal?

Blackstone Life Sciences will pay J&J $750 million over several years to fully fund Phase 3 trials of OLN324, once the acquisition closes. In return, Blackstone can earn regulatory and sales milestone payments plus single-digit royalties, sharing in the upside if the drug reaches the market.

Sources: Johnson & Johnson (via BioSpace), Financial Times, CNBC, Reuters (via Yahoo Finance), BioSpace

How this was made: written with AI assistance from the sources listed above, following our editorial standards.

Back to the latest